Methanobrevibacter smithii

NiFe-Hydrogenase#

Uses nickel-iron clusters ([NiFe] cofactors) to oxidize H2.

In the gut, this enzyme scavenges hydrogen produced by fermentative bacteria (e.g., Bacteroides, Faecalibacterium) (Samuel & Gordon 2006 PNAS;^{[1]The physiological effect of heavy metals and volatile fatty acids on Methanococcus maripaludis S2Abdel Azim A, Rittmann SKR, Fino D et al. · 2018Open reference 1 ↓}).

H2 would otherwise accumulate, creating a hostile reducing environment; methanogenesis by M. smithii converts H2 to the more storable methane. Nickel deprivation eliminates Hydrogenase assembly and suppressively slows methanogenesis, effectively starving M. smithii.

Methyl-Coenzyme M Reductase (Mcr)#

The terminal enzyme in methanogenesis; uses a unique nickel-containing cofactor (nickel (Ni)-F430). Catalyzes the reduction of methyl-CoM to methane; this is the final energy-yielding step. Requires cobalt and iron in addition to nickel for cofactor maturation pathways.

Metal Acquisition#

M. smithii scavenges nickel, cobalt, and iron from the gut lumen via receptor-binding mechanisms. No siderophores synthesized; relies on ferrous iron and nickel supplied by diet or host iron-binding proteins. Elevated hepcidin (host iron-withholding defense) can suppress M. smithii by reducing bioavailable iron (Fe) and nickel (Ni).

Obesity and Metabolic Dysfunction#

Consistently enriched in obese humans across multiple cohorts (Zhang et al. 2009 PNAS; Million et al. 2012 Int J Obes).

Elevated methane producers correlate with constipation, slow intestinal transit, and increased energy harvest from dietary fiber (Pimentel et al. 2006 Dig Dis Sci; Samuel & Gordon 2006 PNAS).

Proposed mechanism: Methane slows intestinal peristalsis via enteric nervous system effects, creating a positive feedback loop (slow transit → more H2 substrate for methanogenesis → more methane → even slower transit).

Increased energy extraction from the same food may drive weight gain (passive caloric surplus).

Irritable Bowel Syndrome (IBS)#

Enriched in constipation-predominant IBS (IBS-C) and normal-transit IBS (Pimentel et al. 2003 Am J Gastroenterol; Kim et al. 2012 J Clin Gastroenterol).

Elevated fecal methane is a diagnostic biomarker for IBS-C (Pimentel et al. 2006 Dig Dis Sci). Methane causes bloating, distention, and altered gut motility.

Multiple Sclerosis (MS)#

Enriched in MS patients; associated with altered gut barrier function and increased LPS translocation (;^{[2]Alterations of the human gut microbiome in multiple sclerosisSushrut Jangi, Roopali Gandhi, Laura M. Cox et al. · 2016Open reference 2 ↓[3]The Gut Microbiota in Multiple Sclerosis Varies with Disease ActivityThirion F, Sellebjerg F, Fan Y et al. · 2023Open reference 3 ↓}).

May contribute to Th17 polarization via altered short-chain fatty acid (SCFA) production (if its H2 consumption reduces acetogenic efficiency) (^{[4]Feeding the gut microbiome: impact on multiple sclerosisMatteo Bronzini, Alessandro Maglione, Rachele Rosso et al. · 2023Open reference 4 ↓}).

Linked to constipation and GI dysfunction common in MS (^{[5]Mediterranean Diet and Associations with the Gut Microbiota and Pediatric-Onset Multiple Sclerosis Using Trivariate AnalysisMirza AI, Zhu F, Knox N et al. · 2024Open reference 5 ↓}).

Cardiovascular Disease (CVD)#

Elevated methanogens associated with altered lipid metabolism and increased bile acid deconjugation (synergy with Collinsella). Methane slows transit → prolonged bile acid reabsorption → altered lipid homeostasis.

Ecological Transitions and Biofilm Formation#

M. smithii does not form biofilms alone but integrates into mixed anaerobic biofilms with bacteria and fungi. In slow-transit Dysbiosis (constipation, megacolon), M. smithii aggregates densely with bacteroides, Prevotella, and Clostridium spp. Reduced peristalsis creates anaerobic microenvironments (lower pO2, more stratified layers), favoring methanogen abundance.

This is distinct from acute dysbiosis (e.g., C. difficile overgrowth), where M. smithii may be secondary to pathogenic dominance.

Molecular Methods#

16S rRNA gene sequencing: Primers targeting archaeal 16S (e.g., ARC344F/ARC915R) distinguish M. smithii from bacterial 16S. Quantitative PCR (qPCR): Genus- or species-specific primers; typical range in healthy gut: 10^6–10^8 copies/g feces. Shotgun metagenomics: M. smithii genome is well-characterized; read abundance correlates with species-level quantification.

Note: Standard bacterial 16S primers often miss archaea; archaeal-specific sequencing required.

Functional Assays#

Methane breath test (MBT): Exhaled methane >20 ppm in breath indicates active methanogenesis; correlates with constipation and M. smithii abundance. FISH (fluorescence in situ hybridization): Archaea-specific probes (e.g., ARCH915) visualize M. smithii in fecal samples. Anaerobic culture: Requires H2 atmosphere and CO2; slow-growing; mainly research setting.